Form 4: Accelerate Diagnostics CFO David Patience Reports Stock Transactions
SEC Form 4 Filing
David Patience, CFO of Accelerate Diagnostics, reports the vesting and sale of restricted stock units to cover tax obligations.
Summary
- On February 26, 2024, David Patience, the Chief Financial Officer of Accelerate Diagnostics, Inc., reported transactions involving the company's common stock.
- Patience vested 1,000 restricted stock units (RSUs) that were granted on February 26, 2022.
- These RSUs represent a contingent right to receive one share of Accelerate Diagnostics' common stock upon vesting.
- To cover tax withholding obligations associated with the vesting of these RSUs, Patience sold 350 shares at a price of $0.96 per share.
- Following these transactions, Patience directly owns 26,247 shares of common stock and indirectly owns 760 shares through a spouse's IRA.
- Patience also continues to hold 1,500 unvested restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock transactions by a company executive. It doesn't indicate any significant positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure related to executive compensation and stock ownership, and is a standard practice for publicly traded companies. It provides transparency into the transactions of company insiders.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units (RSUs) that vest over time, aligning executive interests with long-term shareholder value.
- The 'sell to cover' transaction is a common method for executives to manage tax obligations associated with RSU vesting.
- Similar transactions are regularly reported by executives at comparable companies in the diagnostics and healthcare sectors.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- The sale of shares to cover tax obligations may exert minor downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| 02/26/2022 | Reporting person was granted a total of 2,500 restricted stock units (RSUs). |
| 02/26/2024 | 1,000 RSUs vested and 350 shares were sold to cover tax obligations. |
| 02/26/2025 | Remaining 60% of RSUs (1,500 units) vest. |
| 02/27/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.